Search Bar & Filters
Found 48 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effectiveness of tenapanor in adults with Chronic Idiopathic Constipation CIC. This study is a 26-week, multi-center, randomized, double-blind, placebo-controlled trial followed by a 4-week treatment-free safety follow-up period. It aims to compare three different doses of tenapanor with a placebo taken twice daily to assess their impact on constipation symptoms. The study includes a 2-week screening period to confirm eligibility, followed by a 26-week randomized treatment period where patients receive either 5 mg, 25 mg, or 50 mg of tenapanor twice daily, or a matching placebo. Patients record their constipation symptoms daily in an electronic diary. After the treatment period, there is a 4-week safety follow-up without treatment to monitor any adverse effects. Participants will have regular visits every 2 to 6 weeks for safety checks including medical assessments, vital signs, ECG, and lab tests. Their symptom diaries will be reviewed throughout the study. The main outcome measured is the durable complete spontaneous bowel movements response at 12 weeks. Secondary outcomes include changes in bowel movement frequency, stool consistency, and straining. The total study duration is approximately 32 weeks including all phases.
Actively Recruiting
Researchers are evaluating how well guselkumab works compared to risankizumab in people with moderately to severely active Crohns Disease, a long-term condition causing severe inflammation in the intestines. This Phase 3b study aims to compare the effectiveness and safety of these two treatments to better understand their impact on this condition. Participants will receive either guselkumab or risankizumab following specific dosing schedules. Those receiving guselkumab will get induction doses by subcutaneous injection at Weeks 0, 4, and 8, then maintenance doses every 4 weeks from Week 12 through Week 52. Participants in the risankizumab group will receive induction doses intravenously at Weeks 0, 4, and 8, followed by maintenance doses by subcutaneous injection every 8 weeks from Week 12 to Week 52. During the study, participants will be monitored for deep remission at Week 52, along with other outcomes like clinical remission, endoscopic response, and steroid-free remission. Safety will be assessed by tracking adverse events and lab test abnormalities up to Week 165. Follow-up will continue to evaluate long-term effects, with participant involvement lasting until study completion in 2030.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of JNJ-78934804 compared to guselkumab in adults with moderately to severely active Crohns disease, a long-term and progressive intestinal condition. This Phase 3 study aims to assess how well these treatments work by measuring clinical and endoscopic remission at Week 48. The study is sponsored by Janssen Research & Development, LLC. Participants are randomly assigned to receive either JNJ-78934804 or guselkumab, both given as subcutaneous injections. Treatment starts with induction doses at Weeks 0, 4, and 8, followed by maintenance doses every 4 weeks from Week 12 onward. Those meeting rescue criteria during the study may receive additional induction doses of JNJ-78934804 at Weeks 16, 20, and 24, then continue maintenance dosing from Week 28. After completing the double-blind phase at Week 48, participants who may benefit can join a long-term extension phase. During the study, participants will undergo assessments to measure clinical remission, endoscopic remission, and other outcomes like deep remission and corticosteroid-free remission at various time points. Researchers will monitor patient-reported outcomes, adverse events, and serious adverse events for up to approximately three years. The study involves regular evaluations of disease activity and safety to understand treatment effects and participant well-being over time.
Actively Recruiting
Researchers are evaluating the efficacy and safety of JNJ-78934804 compared to guselkumab in adults with moderately to severely active ulcerative colitis, a chronic condition causing inflammation and ulcers in the colon lining. This phase 3, randomized, double-blind, active-controlled study aims to assess how well these treatments work by measuring clinical remission at Week 48. Participants receive either JNJ-78934804 or guselkumab through subcutaneous injections. Both treatments begin with induction doses at Weeks 0, 4, and 8, followed by maintenance doses every 4 weeks starting at Week 12. Participants who meet rescue criteria during the study may receive additional induction doses of JNJ-78934804 at Weeks 16, 20, and 24, with maintenance continuing every 4 weeks from Week 28. Those completing the initial 48-week treatment phase and deemed to benefit may join a long-term extension phase. Throughout the study, participants undergo assessments including endoscopic evaluations, clinical remission status, symptom scores, quality of life questionnaires, and safety monitoring for adverse events up to approximately 3 years. The primary outcome is the percentage of participants achieving clinical remission at Week 48, with multiple secondary outcomes measured at various time points. This comprehensive evaluation helps understand the treatment effects and safety profile over time.
Actively Recruiting
Researchers are evaluating the use of Vedolizumab in adults with moderate to severely active Ulcerative Colitis UC or Crohns Disease CD. These long-term gut conditions cause symptoms like diarrhea, inflammation, bleeding, and belly pain. The study aims to determine how many participants achieve remission, meaning their symptoms disappear, after 14 weeks of treatment. This is a Phase 4 treatment study sponsored by Takeda. Participants will receive Vedolizumab through two methods. For the first 6 weeks, they get 300 mg intravenously at weeks 0 and 2, with a possible additional dose at week 6. Afterward, starting by week 6 and definitely by week 14, the administration switches to 108 mg injections under the skin every 2 weeks until week 50. Participants who do not respond to treatment by week 14 will stop Vedolizumab and may switch to other treatments, with additional clinic visits at 26 and 52 weeks. A follow-up occurs 18 weeks after the last Vedolizumab dose. Throughout the study, participants have several clinic visits for treatments and assessments. Researchers will measure remission rates using patient-reported outcomes at weeks 6, 14, and 52, alongside clinical response, endoscopic results, and markers like C-reactive protein and fecal calprotectin. Safety is monitored by tracking serious infections up to 72 weeks. The total participation time spans about one year of treatment plus follow-up after treatment ends.
Actively Recruiting
Crohns disease is a long-term condition causing inflammation that can affect any part of the gut. This research aims to evaluate the safety and effectiveness of TAK-279 compared to a placebo in adults with moderately to severely active Crohns disease. The main goal is to find out if three different doses of TAK-279 can reduce bowel inflammation and ulcers after 12 weeks of treatment using endoscopy to assess the bowel. Participants will be randomly assigned to receive one of three doses of TAK-279 or a placebo capsule, taken orally. The treatment period lasts for 52 weeks, or 1 year. The study includes an initial induction phase with treatment assignment and a 4-week safety follow-up phase after completing treatment. The trial is conducted at multiple centers worldwide and involves about 268 participants. Participants will visit the study clinic 15 times during the study. During these visits, researchers will conduct endoscopies and use scores like the Simple Endoscopic Score for Crohns Disease SES-CD and the Crohns Disease Activity Index CDAI to measure inflammation and disease activity. Quality of life and fatigue will also be assessed using questionnaires. Safety and tolerability will be monitored throughout the study and during the follow-up period, with total participation lasting about 60 weeks.
Actively Recruiting
Researchers are studying two surgical procedures to reduce the risk of ovarian cancer in women with BRCA1 genetic mutations. This trial compares bilateral salpingectomy, which removes only the fallopian tubes, with bilateral salpingo-oophorectomy, which removes both fallopian tubes and ovaries. The goal is to find out if removing just the fallopian tubes with delayed ovary removal is nearly as effective as removing both from the start. Participants choose between two groups one undergoes bilateral salpingectomy with the option of later ovary removal, and the other undergoes bilateral salpingo-oophorectomy. Both groups have imaging tests like pelvic ultrasounds or pelvic MRIs during screening and provide blood samples throughout the study. Follow-up visits occur at multiple time points, including 10 to 60 days, 6 months, 12 months, 24 months, and then yearly for up to 20 years. During the study, researchers track if ovarian or related cancers develop and assess symptoms related to estrogen loss, quality of life, cancer-related distress, sexual function, menopausal symptoms, medical decision making, and any adverse events. Various questionnaires and imaging tests support these evaluations. Long-term safety and cancer risk reduction are monitored for up to two decades after surgery.
Actively Recruiting
Researchers are evaluating the efficacy and safety of tulisokibart in people with moderately to severely active Crohns disease. This program includes two separate studies Study 1, which involves both induction and maintenance treatment phases, and Study 2, which includes only the induction treatment phase. The main goals are to see if one or more doses of tulisokibart are better than placebo in achieving clinical remission according to specific Crohns Disease Activity Index scores or stool frequency and abdominal pain scores, and to assess endoscopic response at weeks 12 and 52 depending on the study and regulatory region. Participants receive tulisokibart either intravenously or subcutaneously at different dose levels depending on the study arm. Some receive a high dose induction followed by high or low dose maintenance, others receive low dose throughout, and some receive placebo. Extension arms allow participants who complete their original treatment to continue receiving high or low dose subcutaneous tulisokibart if they qualify. The study uses random assignment to treatment groups and is double-blind, meaning neither participants nor researchers know who receives the drug or placebo. Throughout the studies, participants undergo evaluations at specified weeks to measure clinical remission, clinical response, endoscopic response, and other outcomes such as fatigue and quality of life. Safety is monitored by tracking adverse events and discontinuations due to side effects. The overall participation may last up to 52 weeks for Study 1 and 12 weeks for Study 2, with assessments at multiple points to carefully observe treatment effects and safety.
Actively Recruiting
Researchers are evaluating the effectiveness of vonoprazan 10 mg taken as needed compared to a placebo for relieving episodic heartburn in adults with symptomatic non-erosive gastroesophageal reflux disease GERD. The study focuses on heartburn relief at 2 hours sustained for 24 hours, assessing outcomes over a 12-week treatment period. This phase 3, randomized, double-blind trial aims to provide insight into vonoprazans role in managing this condition. Participants first undergo a 4-week open-label run-in period where they take vonoprazan 10 mg once daily orally. During the following 12-week placebo-controlled timed assessment period and an additional 12-week placebo-controlled extension period, participants are randomly assigned to receive either vonoprazan 10 mg or placebo taken orally as needed at the onset of heartburn episodes, limited to once every 24 hours. Throughout the study, participants will record heartburn episodes in an electronic diary to track frequency and response to treatment. Researchers will measure the percentage of treated heartburn episodes achieving complete relief at 2 hours with sustained relief for 24 hours up to week 12 as the primary outcome. Secondary outcomes include heartburn improvement at various time points up to week 24. Safety and compliance will be monitored, with the total study duration extending through 24 weeks.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of camlipixant in adults diagnosed with irritable bowel syndrome with diarrhea IBS-D and mixed irritable bowel syndrome IBS-M. This phase 2b study is designed to compare camlipixant with a placebo in relieving abdominal symptoms. The study includes two parts, with some participants randomly assigned in the second part to receive either a higher dose of the drug or to stop treatment. Participants will receive different doses of camlipixant or placebo during the first part of the study. In the second part, participants may receive either placebo or camlipixant again, allowing researchers to assess the effects of dose adjustments. The dosing levels include three different doses of camlipixant compared with placebo. The study treatment is given under double-blind conditions, meaning neither participants nor researchers know who receives which treatment. Throughout the study, participants will be monitored for changes in abdominal pain intensity and stool consistency over 12 weeks, with safety assessments continuing up to 26 weeks. Researchers will collect data on abdominal pain scores, stool form, global improvement, and any side effects or adverse events. Regular evaluations include physical exams, laboratory tests, and heart monitoring. Participants are expected to be involved in scheduled visits and assessments to track the study outcomes and ensure safety.
1-10 of 48
1